VEGFA and age-related macular degeneration: Two therapeutic strategies are currently available to switch off AMD-related CNV and reduce its dramatic effects on patient’s vision: the intravitreally administrated drugs acting against vascular endothelial growth factor (anti-VEGF) and, as second-line treatment, the photodynamic therapy with verteporfin (PDT-V)22–31.